| Expression pattern: |
DN |
| Associated gene: |
BTG2 |
| Associated microRNA: |
miR-216a-3p |
| Biological function: |
inhibits proliferation, invasion and migration; inhibits EMT; inhibits stemness |
| Molecular mechanism: |
circFLNA sponges miR-216a-3p to promote BTG2 expression |
| Biological pathway or process: |
proliferation (inhibits); invasion (inhibits); migration (inhibits); EMT (inhibits); stemness (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Nuclear-Cytoplasmic Fractionation; Transfection; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Luciferase Reporter Assay; RNA Pull-Down; Western Blot; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
circFLNA/miR-216a-3p/BTG2 can be used as a BCa biomarker and a potential therapeutic target |
| Description: |
circFLNA is down-regulated in bladder carcinoma tissues and cell lines. circFLNA suppresses malignant phenotypes (proliferation, migration, invasion), EMT and stemness by acting as a ceRNA that sponges miR-216a-3p, thereby releasing BTG2 expression. |
| Confidence score: |
0.7295 |